Efficacy News and Research

RSS

Laparoscopic radical cystectomy can lead to reliable, long-term cancer control

Long-term survival rates following laparoscopic surgery for bladder cancer are comparable to those of open surgery, according to a study published in BJU International. The findings, which come from the largest study to date with long-term follow-up after this type of minimally invasive surgery, indicate that prospective randomized trials comparing these two bladder cancer surgeries are warranted.

18 Dec 2014

High-dose flu vaccine better than regular flu shot for frail, older adults of long-term care facilities

The high-dose flu vaccine is significantly better than the regular flu shot at boosting the immune response to the flu virus in frail, older residents of long-term care facilities, according to the results of a University of Pittsburgh School of Medicine study.

18 Dec 2014

AAN urges for more research on use of medical marijuana for brain, nervous system disorders

The American Academy of Neurology is calling for more research on the use of medical marijuana for brain, spine and nervous system disorders in a new position statement released by the AAN, the world's largest association of neurologists with more than 28,000 members.

18 Dec 2014

University Hospital Bonn to validate accuracy of VolitionRx’s Nucleosomics technology in lung cancer

VolitionRx Limited, a life sciences company focused on developing diagnostic tests for cancer and other conditions, today announced that the University Hospital Bonn in Germany will initiate a clinical confirmatory study to assess VolitionRx’s proprietary Nucleosomics platform technology for the diagnosis of lung cancer through a blood test in individuals.

18 Dec 2014

Diabetes drug can boost efficacy of TB medication without causing drug resistance

A more effective treatment for tuberculosis (TB) could soon be available as scientists have discovered that Metformin (MET), a drug for treating diabetes, can also be used to boost the efficacy of TB medication without inducing drug resistance.

17 Dec 2014

Antipsychotic polypharmacy prevalent despite efficacy doubts

Results of a retrospective study suggest that around a quarter of patients with schizophrenia receive antipsychotic polypharmacy, despite a lack of evidence for the approach.

17 Dec 2014

Emerging evidence suggests electronic cigarettes can help smokers quit

New Cochrane review finds emerging evidence that smokers who use electronic cigarettes can stop or reduce their smoking.

17 Dec 2014

Study provides new evidence for anti-cirrhotic effects of GENFIT's GFT505

GENFIT, a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect the liver or the gastrointestinal system, today announces that a recent study provides new evidence for anti-cirrhotic effects of GFT505 in the context of NASH.

17 Dec 2014

Lilly receives FDA approval for CYRAMZA (ramucirumab)

Eli Lilly and Company has received its third U.S. Food and Drug Administration approval for CYRAMZA (ramucirumab).

16 Dec 2014

Pre-clinical studies confirm TRXE-009 as new potential treatment for melanoma

Novogen Limited, Australian/US biotechnology company, today announces that it has confirmed that its lead candidate product, TRXE-009, originally developed for the treatment of brain cancers, has been shown in pre-clinical studies also to be highly active against melanoma.

16 Dec 2014

CARLINA, Atlangram partner to develop antibiotics for osteoarticular infectious diseases

CARLINA Technologies, a biotechnology company specializing in the development of nanomedicines, today announces the signing of a partnership agreement with Atlangram for the development of innovative pharmaceutical forms of antibiotics for the targeting of osteoarticular infectious diseases.

16 Dec 2014

Curie-Cancer, GamaMabs Pharma extend partnership to develop 3C23K drug for gynecological cancers

Curie-Cancer, the body responsible for developing Institut Curie’s industry partnership activities, and GamaMabs Pharma, a company specialized in the development of monoclonal antibodies for cancer, today announce the extension of their partnership to develop the 3C23K antibody for the treatment of gynecological cancers.

16 Dec 2014

ARA 290 drug reduces neuropathic pain in type 2 diabetic patients

Molecular Medicine, a peer-reviewed biomedical journal published by the Feinstein Institute Press, published the results of a new study reporting clinically significant pain reduction in type 2 diabetic patients. In an exploratory study conducted by Araim Pharmaceuticals, a biotech company developing novel treatments for chronic diseases, investigators also observed improvements in metabolic control in patients administered ARA 290.

16 Dec 2014

New 3-D imaging catheter aims to reduce risk of complications during cardiac interventions

An emerging 3-D imaging catheter aims to provide cardiologists with a live view from inside the heart during cardiac catheterizations. Developed by RTI International, the catheter contains an ultrasound microarray made using semiconductor circuit fabrication that can provide unprecedented volumetric field-of-view, in real time.

16 Dec 2014

Trastuzumab drug improves long-term survival of patients with HER-2 positive breast cancer

VCU Massey Cancer Center physician-researcher Charles E. Geyer, Jr., M.D., was the National Protocol Officer for one component of a large national study involving two National Cancer Institute-supported clinical trials that demonstrated that trastuzumab significantly improves the long-term survival of HER-2 positive breast cancer patients.

16 Dec 2014

FL118 agent shows efficacy as personalized, targeted therapy for certain cancer tumors

A team led by Fengzhi Li, PhD, and Xinjiang Wang, PhD, of Roswell Park Cancer Institute has reported new findings regarding therapeutic targets of the novel anticancer agent FL118. Previous studies from these researchers have showed that FL118 induces cancer cell death, or apoptosis, by inhibiting expression of multiple cell-survival proteins (survivin, Mcl-1, XIAP or cIAP2).

15 Dec 2014

TWi Biotechnology gets approval of Phase II clinical trial protocol for AC-201 CR tablets

TWi Pharmaceuticals, Inc. today announced that its fully owned subsidiary, TWi Biotechnology, Inc., has received US FDA and Taiwan FDA approval of a protocol for a Phase II clinical trial of its AC-201 controlled-release (CR) tablets for the indications of high blood uric acid level and gout.

14 Dec 2014

Efficacy News and Research

Laparoscopic radical cystectomy can lead to reliable, long-term cancer control

High-dose flu vaccine better than regular flu shot for frail, older adults of long-term care facilities

AAN urges for more research on use of medical marijuana for brain, nervous system disorders

University Hospital Bonn to validate accuracy of VolitionRx’s Nucleosomics technology in lung cancer

Diabetes drug can boost efficacy of TB medication without causing drug resistance

Antipsychotic polypharmacy prevalent despite efficacy doubts

Emerging evidence suggests electronic cigarettes can help smokers quit

Study provides new evidence for anti-cirrhotic effects of GENFIT's GFT505

Lilly receives FDA approval for CYRAMZA (ramucirumab)

Pre-clinical studies confirm TRXE-009 as new potential treatment for melanoma

CARLINA, Atlangram partner to develop antibiotics for osteoarticular infectious diseases

Curie-Cancer, GamaMabs Pharma extend partnership to develop 3C23K drug for gynecological cancers

ARA 290 drug reduces neuropathic pain in type 2 diabetic patients

New 3-D imaging catheter aims to reduce risk of complications during cardiac interventions

Trastuzumab drug improves long-term survival of patients with HER-2 positive breast cancer

FL118 agent shows efficacy as personalized, targeted therapy for certain cancer tumors

TWi Biotechnology gets approval of Phase II clinical trial protocol for AC-201 CR tablets

New study compares usefulness of two biomarkers released into the blood after TBI

NTU scientists discover how malaria parasite develops resistance towards front-line drugs

Scientific collaboration reveals encouraging insight on AMD disease

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News